1-3 of 3
Caroline Roudet, PharmD, MBA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma

Farrukh T. Awan, MD MS, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Ajay K. Gopal, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5322.
https://doi.org/10.1182/blood-2018-99-110477
Published: 2018
Journal Articles

Idelalisib Plus Anti-CD20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL

Jennifer R. Brown, MD PhD, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Susan M. O'Brien, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5564.
https://doi.org/10.1182/blood-2018-99-110853
Published: 2018
Journal Articles

Survival Outcomes Following Idelalisib Interruption in the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Shuo Ma, MD PhD, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Carrie Ellen Brubaker, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Nina D. Wagner-Johnston, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3149.
https://doi.org/10.1182/blood-2018-99-110655
Published: 2018